M2T™ Program (unspecified)
Acute Myeloid Leukemia (AML)
Key Facts
About Leukogene Therapeutics
Leukogene Therapeutics is a private, preclinical-stage biotech company spun out from the Medical University of South Carolina (MUSC) and headquartered in Charleston, SC, with a presence in San Diego. The company is pioneering a novel immunotherapy approach that targets MHC class II to activate a coordinated, tumor antigen-specific immune response, aiming to overcome limitations of existing therapies. Its lead programs are in acute myeloid leukemia (AML) and pancreatic ductal adenocarcinoma (PDAC), with demonstrated preclinical proof of concept. Leukogene is backed by the National Cancer Institute (NCI) and SCRA SC Launch.
View full company profileAbout Leukogene Therapeutics
Leukogene Therapeutics is a private, preclinical-stage biotech company spun out from the Medical University of South Carolina (MUSC) and headquartered in Charleston, SC, with a presence in San Diego. The company is pioneering a novel immunotherapy approach that targets MHC class II to activate a coordinated, tumor antigen-specific immune response, aiming to overcome limitations of existing therapies. Its lead programs are in acute myeloid leukemia (AML) and pancreatic ductal adenocarcinoma (PDAC), with demonstrated preclinical proof of concept. Leukogene is backed by the National Cancer Institute (NCI) and SCRA SC Launch.
View full company profileTherapeutic Areas
Other Acute Myeloid Leukemia (AML) Drugs
| Drug | Company | Phase |
|---|---|---|
| Mipletamig (APVO436) | Aptevo Therapeutics | Phase 1/2 |
| lomonitinib | Lomond Therapeutics | IND-Enabling |
| lonitoclax | Lomond Therapeutics | Phase 1 |
| Menin Inhibitor | Lomond Therapeutics | Discovery |
| AB8939 | AB Science | Phase 1 |
| Small-Molecule Therapeutic | AIkido Labs | Pre-clinical |
| ADI-PEG 20 (pegargiminase) | Polaris Pharma | Phase 1 |
| NC525 | NextCure | Preclinical |
| ACD-101 | Advanced Cellular Dynamics | Phase 1 |
| ABD-3001 | Advanced Biodesign | Phase 1 |
| HC-7366 | HiberCell | Phase 1b |
| Prexigebersen (BP1001) | Bio-Path Holdings | Phase 2 |